Section 6 of 6
References
143 sources
- Adrichem et al. (2022) (opens in a new tab)
- Al-Zuhairy and Jakobsen (2023) (opens in a new tab)
- Al-Zuhairy et al. (2020) (opens in a new tab)
- Allen and Lewis (2015) (opens in a new tab)
- Allen et al. (2018) (opens in a new tab)
- Allen et al. (2020) (opens in a new tab)
- Allen et al. (2021) (opens in a new tab)
- Allen et al. (2024) (opens in a new tab)
- Allen et al. (2026c) (opens in a new tab)
- Allen et al. (2026d) (opens in a new tab)
- Allen et al. (2026e) (opens in a new tab)
- ANZCTR ACTRN12622001265763 (opens in a new tab)
- ANZCTR ACTRN12624000352505 (opens in a new tab)
- Aotsuka et al. (2024) (opens in a new tab)
- argenx annual report (2026) (opens in a new tab)
- Bamrungsawad et al. (2016) (opens in a new tab)
- Blackhouse et al. (2010) (opens in a new tab)
- Blein et al. (2025) (opens in a new tab)
- Brackx et al. (2026) (opens in a new tab)
- Breiner et al. (2014) (opens in a new tab)
- Bril et al. (2023) (opens in a new tab)
- Broers et al. (2019) (opens in a new tab)
- Broers et al. (2021) (opens in a new tab)
- Bus et al. (2024) (opens in a new tab)
- Bus et al. (2026) (opens in a new tab)
- CDA-AMC efgartigimod alfa reimbursement recommendation (2026) (opens in a new tab)
- CDA-AMC efgartigimod alfa reimbursement review (2026) (opens in a new tab)
- Choi et al. (2024) (opens in a new tab)
- ClinicalTrials.gov NCT04281472 (opens in a new tab)
- ClinicalTrials.gov NCT06290128 (opens in a new tab)
- ClinicalTrials.gov NCT06290141 (opens in a new tab)
- ClinicalTrials.gov NCT06858579 (opens in a new tab)
- ClinicalTrials.gov NCT06920004 (opens in a new tab)
- ClinicalTrials.gov NCT07091630 (opens in a new tab)
- ClinicalTrials.gov NCT07647510 (opens in a new tab)
- Cook et al. (2023) (opens in a new tab)
- Cornblath et al. (2022) (opens in a new tab)
- Dalakas (2022) (opens in a new tab)
- De Lorenzo et al. (2024) (opens in a new tab)
- de Pedro et al. (2026) (opens in a new tab)
- Dianthus Therapeutics (2022) (opens in a new tab)
- Dianthus Therapeutics (2023) (opens in a new tab)
- Dianthus Therapeutics (2024b) (opens in a new tab)
- Dianthus Therapeutics (2025a) (opens in a new tab)
- Dianthus Therapeutics (2026a) (opens in a new tab)
- Dianthus Therapeutics (2026e) (opens in a new tab)
- Dianthus Therapeutics (2026g) (opens in a new tab)
- Dianthus Therapeutics Form 10-K (2025) (opens in a new tab)
- Dianthus Therapeutics Form 10-K (2026) (opens in a new tab)
- Dianthus Therapeutics Form 10-Q (2026a) (opens in a new tab)
- Dianthus Therapeutics Form 10-Q (2026c) (opens in a new tab)
- Dianthus Therapeutics Form 8-K (2026) (opens in a new tab)
- Dianthus Therapeutics presentation (2024a) (opens in a new tab)
- Dianthus Therapeutics presentation (2024b) (opens in a new tab)
- Dianthus Therapeutics presentation (2026a) (opens in a new tab)
- Dianthus Therapeutics presentation (2026b) (opens in a new tab)
- Dianthus Therapeutics presentation (2026c) (opens in a new tab)
- Dianthus Therapeutics presentation (2026d) (opens in a new tab)
- Dianthus Therapeutics presentation (2026e) (opens in a new tab)
- Divino et al. (2018) (opens in a new tab)
- Draak et al. (2014) (opens in a new tab)
- Dyck et al. (1986) (opens in a new tab)
- Eftimov et al. (2012) (opens in a new tab)
- EU Clinical Trials Information System 2024-517529-26-00 (opens in a new tab)
- Figueroa et al. (2012) (opens in a new tab)
- Gable et al. (2026) (opens in a new tab)
- Gammagard Liquid prescribing information (2024) (opens in a new tab)
- Gamunex-C prescribing information (2026) (opens in a new tab)
- Gokhale et al. (2024) (opens in a new tab)
- Guptill et al. (2014) (opens in a new tab)
- Guptill et al. (2019) (opens in a new tab)
- Guptill et al. (2024) (opens in a new tab)
- Hadden et al. (2015) (opens in a new tab)
- Hadden et al. (2024) (opens in a new tab)
- Hafsteinsdottir and Olafsson (2016) (opens in a new tab)
- Hahn et al. (1996) (opens in a new tab)
- Hauw et al. (2021) (opens in a new tab)
- Hizentra prescribing information (2021) (opens in a new tab)
- Hughes et al. (2001) (opens in a new tab)
- Hughes et al. (2008) (opens in a new tab)
- Hughes et al. (2017) (opens in a new tab)
- HyQvia prescribing information (2026) (opens in a new tab)
- Jung et al. (2023) (opens in a new tab)
- Katzberg et al. (2024) (opens in a new tab)
- Koay et al. (2025) (opens in a new tab)
- Laughlin et al. (2009) (opens in a new tab)
- Layton et al. (2023) (opens in a new tab)
- Léger et al. (2013) (opens in a new tab)
- Lemmen et al. (2025) (opens in a new tab)
- Mahdi-Rogers et al. (2017) (opens in a new tab)
- Mallick et al. (2025) (opens in a new tab)
- Marsh et al. (2021) (opens in a new tab)
- McCrone et al. (2003) (opens in a new tab)
- Mehndiratta et al. (2015) (opens in a new tab)
- Mengel et al. (2018) (opens in a new tab)
- Merkies et al. (2000) (opens in a new tab)
- Merkies et al. (2009) (opens in a new tab)
- Michaelides et al. (2019) (opens in a new tab)
- Min et al. (2025) (opens in a new tab)
- Muley et al. (2026) (opens in a new tab)
- Murakami et al. (2026) (opens in a new tab)
- NICE ID6409 draft guidance (2026) (opens in a new tab)
- NICE ID6409 project information (2026) (opens in a new tab)
- Nobile-Orazio et al. (2012) (opens in a new tab)
- Nobile-Orazio et al. (2025) (opens in a new tab)
- Nowacek et al. (2025) (opens in a new tab)
- Okonkwo et al. (2025) (opens in a new tab)
- Pallada et al. (2026) (opens in a new tab)
- Panzyga prescribing information (2021) (opens in a new tab)
- Pasangulapati et al. (2017) (opens in a new tab)
- Pasnoor et al. (2025) (opens in a new tab)
- Privigen prescribing information (2025) (opens in a new tab)
- Querol et al. (2021) (opens in a new tab)
- Querol et al. (2022) (opens in a new tab)
- Querol et al. (2025) (opens in a new tab)
- Querol et al. (2026a) (opens in a new tab)
- Querol et al. (2026d) (opens in a new tab)
- Quint et al. (2024) (opens in a new tab)
- Rajabally and Cavanna (2015) (opens in a new tab)
- Rajabally et al. (2025) (opens in a new tab)
- RMC Trial Group (2009) (opens in a new tab)
- Rumsey et al. (2022) (opens in a new tab)
- Sanofi (2026) (opens in a new tab)
- Sommer et al. (2026) (opens in a new tab)
- Stascheit et al. (2025) (opens in a new tab)
- Stascheit et al. (2026) (opens in a new tab)
- Van den Bergh et al. (2021) (opens in a new tab)
- van Doorn et al. (2024) (opens in a new tab)
- van Doorn et al. (2026) (opens in a new tab)
- van Nes et al. (2011) (opens in a new tab)
- van Schaik et al. (2010) (opens in a new tab)
- van Schaik et al. (2016) (opens in a new tab)
- van Schaik et al. (2018) (opens in a new tab)
- van Schaik et al. (2019) (opens in a new tab)
- Vanhoutte et al. (2013) (opens in a new tab)
- Vissing et al. (2024) (opens in a new tab)
- Vu et al. (2026b) (opens in a new tab)
- Vyvgart Hytrulo prescribing information (2026) (opens in a new tab)
- WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
- WHO Drug Information Recommended INN List 94 (2025) (opens in a new tab)
- WHO INN monoclonal antibody nomenclature scheme (2022) (opens in a new tab)
- WHO Proposed INN List 132 (2024) (opens in a new tab)
- Yang et al. (2026) (opens in a new tab)